BETHESDA, Md.--(BUSINESS WIRE)--March 7, 2006--RegeneRx Biopharmaceuticals, Inc. (AMEX:RGN) announced today that it has obtained commitments to purchase shares of its common stock in a registered direct offering of approximately $7.3 million at $2.81 per share. Participants in the financing included several new institutional investors, and affiliates of Sigma-Tau Group, the Company’s largest stockholder. The shares were offered through a prospectus supplement pursuant to the Company’s effective shelf registration statement. In addition, warrants to purchase 907,182 shares of common stock were issued to the investors. The warrants have an exercise price of $4.06 per share.
